Premium
Cladribine followed by autologous stem‐cell transplantation in progressive multiple sclerosis
Author(s) -
Grigg A.,
Tubridy N. J.,
Szer J.,
Mitchell P.,
Butzkueven H.,
Shuttleworth P.,
Kilpatrick T.
Publication year - 2004
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1444-0903.2004.00516.x
Subject(s) - medicine , cladribine , filgrastim , multiple sclerosis , transplantation , cyclophosphamide , autologous stem cell transplantation , stem cell , surgery , hematopoietic stem cell transplantation , granulocyte colony stimulating factor , immunology , chemotherapy , biology , genetics
We studied the safety of autologous peripheral blood stem‐cell transplantation (PBSCT) in four patients with progressive multiple sclerosis. Clinical and magnetic resonance imaging outcomes were secondary end‐points. Cladribine administration preceded filgrastim‐primed PBSC collection, aiming for lymphocyte depletion. Conditioning was with antithymocyte globulin and cyclophosphamide. The procedure was well tolerated, but without obvious clinical benefit. The study was terminated when other therapeutic options with lower morbidity became available. (Intern Med J 2004; 34: 66−69)